ARKG — ARK Genomic Revolution ETF
Healthcare Ranked #209 of 458 tracked ETFs · Issued by ARK ETF Trust
ARKG Price Performance — Growth of $10,000
Value of a $10,000 investment in ARKG over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.
ARKG Drawdown
The "underwater" chart: ARKG's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.
What If You'd Invested in ARKG?
See what a lump sum in ARKG would have grown to, with the option to add a regular monthly contribution on top. Figures use total returns — dividends are assumed reinvested.
Past performance doesn't predict future results. Assumes contributions on the first trading day of each month, no trading costs or taxes, and reinvested distributions. History is limited to the range published in the site's daily return data.
Overview
The ARK Genomic Revolution ETF is a healthcare-focused fund issued by ARK ETF Trust with $2.22 billion in assets. It holds a C grade, ranking 9th out of 11 peers in its category and 209th of 458 tracked ETFs overall. The 0.75% expense ratio exceeds the category median of 0.36%, while the fund provides no dividend yield compared to the median 0.98%. Concentration is notable, with the top 10 holdings comprising 59.1% of assets and the largest position, 10X GENOMICS INC, accounting for 9.4%.
Price action shows the fund trading at $48.16, which sits at 68.8% of its 52-week range. Short-term momentum has been mixed, with a 1-day gain of 0.61% contrasting against a 1-month decline of 10.03%. However, longer horizons display strong acceleration, including a 1-year return of 57.54% and a 3-year total of 114.71%. These figures significantly outpace the category median 1-year return of 24.88%. The C grade has remained unchanged over the last 35 tracked days, based on 3.0 years of available price history.
The fund exhibits Very High volatility at 44.66% annualized, paired with a beta of 2.21 indicating substantial movement relative to the market. This leverage to market swings is reflected in a maximum drawdown of -46.45%. Despite the elevated risk, the Sharpe ratio of 1.18 suggests the returns generated have compensated for that volatility. Trading liquidity is supported by an average daily volume of 4,316,485 shares.
AI-generated summary based on the data on this page.
ARKG Top Holdings
| # | Holding | % of Net Assets | Value |
|---|---|---|---|
| 1 | 10X GENOMICS INC | 9.39% | $146M |
| 2 | TWIST BIOSCIENCE CORP | 7.73% | $120M |
| 3 | TEMPUS AI INC | 6.56% | $102M |
| 4 | CRISPR THERAPEUTICS AG | 6.29% | $98M |
| 5 | PERSONALIS INC | 5.47% | $85M |
| 6 | ABSCI CORP | 5.14% | $80M |
| 7 | GUARDANT HEALTH INC | 4.74% | $74M |
| 8 | ILLUMINA INC | 4.74% | $74M |
| 9 | ELI LILLY & COMPANY | 4.68% | $73M |
| 10 | CAREDX INC | 4.30% | $67M |
Holdings as of 2026-07-31 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 59.1% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how ARKG's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.
Which Funds Overlap With ARKG
Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with ARKG's top 10 — ARKK overlaps most, holding 3 of the same companies as ARKG's top 10 (20.6% of ARKG's assets).
| ETF | Name | Shared Companies | ARKG Weight | Examples |
|---|---|---|---|---|
| ARKK | ARK Innovation ETF | 3 | 20.6% | TEMPUS AI INC, TWIST BIOSCIENCE CORP, CRISPR THERAPEUTICS AG |
| XBI | State Street SPDR S&P Biotech ETF | 1 | 7.7% | TWIST BIOSCIENCE CORP |
| IJH | iShares Core S&P Mid-Cap ETF | 1 | 4.7% | ILLUMINA INC |
| ROBO | Robo Global Robotics and Automation Index ETF | 1 | 4.7% | ILLUMINA INC |
| SPMD | State Street SPDR Portfolio S&P 400 Mid Cap ETF | 1 | 4.7% | ILLUMINA INC |
Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.
Market Backdrop
10-Year Treasury Yield: 4.96% (as of 2026-10-22) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.
CBOE Volatility Index (VIX): 19.03 (as of 2026-10-22) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.
Federal Funds Rate: 3.75% (as of 2026-09-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.
What ARKG's Fees Cost You
ARKG charges an expense ratio of 0.75% a year, deducted automatically from the fund's value. Small percentages compound into real money — adjust the figures below to see the impact on your own numbers.
Assumes a constant gross return and no additional contributions — a simplification, but it isolates exactly what the expense ratio costs. Try the full fee calculator to model contributions and compare any two funds.
ARKG Liquidity, Domicile & Tax Treatment
Liquidity: Average daily volume is 4.3M/day. Higher volume and a larger fund generally mean lower round-trip trading costs. AUM of $2.22B provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.
Domicile & tax treatment: ARKG is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.
ARKG Performance History
| Period | Return |
|---|---|
| 1-Day | +0.61% |
| 1-Week | +3.13% |
| 1-Month | -10.03% |
| 3-Month | +27.44% |
| 6-Month | +63.03% |
| YTD | +65.04% |
| 1-Year | +57.54% |
| 3-Year | +114.71% |
How ARKG Compares to Other Healthcare ETFs
| Rank | Grade | Ticker | Name | 1-Year | Exp. Ratio | AUM |
|---|---|---|---|---|---|---|
| #31 | B+ |
XLV | State Street Health Care Select Sector SPDR ETF | +24.88% | 0.08% | $43.4B |
| #36 | B+ |
VHT | Vanguard Health Care Index Fund ETF Shares | +24.24% | 0.09% | $21.8B |
| #64 | B |
FHLC | Fidelity MSCI Health Care Index ETF | +24.43% | 0.084% | $3.54B |
| #100 | B |
IBB | iShares Biotechnology ETF | +35.23% | 0.44% | $11.2B |
| #106 | B |
XBI | State Street SPDR S&P Biotech ETF | +39.94% | 0.35% | $10.4B |
| #125 | B |
IYH | iShares U.S. Healthcare ETF | +24.20% | 0.37% | $3.96B |
| #140 | B |
PPH | VanEck Pharmaceutical ETF | +27.00% | 0.36% | $1.02B |
| #175 | B |
XPH | State Street SPDR S&P Pharmaceuticals ETF | +29.81% | 0.35% | $524M |
| #209 | C |
ARKG | ARK Genomic Revolution ETF | +57.54% | 0.75% | $2.22B |
| #297 | C |
IHF | iShares U.S. Healthcare Providers ETF | +19.55% | 0.37% | $1.36B |
| #424 | D |
IHI | iShares U.S. Medical Devices ETF | -11.17% | 0.37% | $3.45B |